@article{oai:nagasaki-u.repo.nii.ac.jp:00005643,
 author = {Yamaguchi, Yoshiyuki and Yamaue, Hiroki and Okusaka, Takuji and Okuno, Kiyotaka and Suzuki, Hiroyuki and Fujioka, Tomoaki and Otsu, Atsushi and Ohashi, Yasuo and Shimazawa, Rumiko and Nishio, Kazuto and Furuse, Junji and Minami, Hironobu and Tsunoda, Takuya and Hayashi, Yuzo and Nakamura, Yusuke},
 issue = {7},
 journal = {Cancer Science},
 month = {Jul},
 note = {Recent progress in fundamental understanding of tumor immunology has opened a new avenue of cancer vaccines. Currently, the development of new cancer vaccines is a global topic and has attracted attention as one of the most important issues in Japan. There is an urgent need for the development of guidance for cancer vaccine clinical studies in order to lead to drug development. Peptide vaccines characteristically have the effect of indirectly acting against cancer through the immune system - a mechanism of action that clearly differs from anticancer drugs that exert a direct effect. Thus, the clinical development of cancer peptide vaccines should be planned and implemented based on the mechanism of action, which differs significantly from conventional anticancer drug research. The Japanese Society for Biological Therapy has created and published Guidance for peptide vaccines for the treatment of cancer as part of its mission and responsibilities towards cancer peptide vaccine development, which is now pursued globally. We welcome comments from regulators and business people as well as researchers in this area. Guidance for Peptide Cancer Vaccines., Cancer Science, 105(7), pp.924-931; 2014},
 pages = {924--931},
 title = {Guidance for peptide vaccines for the treatment of cancer},
 volume = {105},
 year = {2014}
}